References
- Aggarwal BB, Shishodia S (2006): Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71: 1397–1421.
- Ball KR, Kowdley KV (2005): A review of Silybum marianum. (milk thistle) as a treatment for alcoholic liver disease. J Clin Gastroenterol 39: 520–528.
- Bhatia N, Zhao J, Wolf DM, Agarwal R (1999): Inhibition of human carcinoma cell growth and DNA synthesis by silibinin, an active constituent of milk thistle: Comparison with silymarin. Cancer Lett 147: 77–84.
- Crocenzi FA, Roma MG (2006): Silymarin as a new hepatoprotective agent in experimental cholestasis: New possibilities for an ancient medication. Curr Med Chem 13: 1055–1074.
- Dhiman RK, Chawla YK (2005): Herbal medicines for liver diseases. Dig Dis Sci 50: 1807–1812.
- Flaig TW, Gustafson DL, Su L-J, Zirrolli JA, Crighton F, Harrison GS, Pierson AS, Agarwal R, Glode LM (2007): A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs 25: 139–146.
- Flora K, Hahn M, Rosen H, Benner K (1998): Milk thistle (Silybum marianum.) for the therapy of liver disease. Am J Gastroenterol 93: 140–143.
- Henle G, Henle W (1966): Immunofluorescence in cells derived from Burkitt's lymphoma. J Bacteriol 91: 1248–1256.
- Jacobs BP, Dennehy C, Ramirez G, Sapp J, Lawrence V (2002): Milk thistle for the treatment of liver disease: A systematic review and meta-analysis. Am J Med 113: 506–515.
- Katiyar S (2005): Silymarin and skin cancer prevention: Anti-inflammatory, antioxidant and immunomodulatory effects (review). Int J Oncol 26: 169–176.
- Lee DY-W, Liu Y (2003): Molecular structure and stereochemistry of silybin A, silybin B, isosilybin A, and isosilybin B, isolated from Silybum marianum. (milk thistle). J Nat Prod 66: 1171–1174.
- Luper S (1998): A review of plants used in the treatment of liver disease: Part 1. Altern Med Rev 3: 410–421.
- Rambaldi A, Jacobs BP, Iaquinto G, Gluud C (2005): Milk thistle for alcoholic and/or hepatitis B or C liver diseases—a systematic Cochrane hepato-biliary group review with meta-analyses of randomized clinical trials. Am J Gastroenterol 100: 2583–2591.
- Singh RP, Agarwal R (2005): Mechanisms and preclinical efficacy of silibinin in preventing skin cancer. Eur J Cancer 41: 1969–1979.
- Smith WA, Lauren DR, Burgrss EJ, Perry NB, Martin RJ (2005): A silychristin isomer and variation of flavonolignan levels in milk thistle (Silybum marianum.) fruits. Planta Med 71: 877–880.
- Suzuki M, Nakagawa-Goto K, Nakamura S, Tokuda H, Morris-Natschke SL, Kozuka M, Nishino H, Lee K-H (2006): Cancer preventive agents. Part 5. Anti-tumor-promoting effects of coumarins and related compounds on Epstein-Barr virus activation and two-stage mouse skin carcinogenesis. Pharm Biol 44: 178–182.
- Takasaki M, Konoshima T, Fujitani K, Yoshida A, Nishimura H, Tokuda H, Nishino H, Iwashima A, Kozuka M (1990): Inhibitors of skin-tumor promotion. VIII. Inhibitory effects of euglobals and their related compounds on Epstein-Barr virus activation. (1). Chem Pharm Bull 38: 2737–2739.
- Wang X, Nakagawa-Goto K, Kozuka M, Tokuda H, Nishino H, Lee K-H (2006): Cancer preventive agents. Part 6: Chemopreventive potential of furanocoumarins and related compounds. Pharm Biol 44: 116–120.